Pancreatic Cancer
Advertisement
Dr. Strosberg focuses on how previous exposure to alkylating agents can influence tumor biology or immune response.
Dr. Pant shared updates on a phase 1b dose escalation trial of gemcitabine, nab-paclitaxel, and lixumistat.
Dr. Shirakawa highlighted the results of the NAPOLEON-2 trial, including how RWD compare to clinical trial findings.
Dr. Dotan shared the effects of baseline geriatric and QOL assessments on outcomes for older patients with pancreatic cancer.
Dr. Abdelrahim details the impact of UGT1A1*28 polymorphism on tolerability in patients with mPDAC in the NAPOLI 3 study.
Results of NIR-B trial sheds light on the clinical utility of niraparib in patients with BRCA-mutated GI cancers.
A novel auto-segmentation model and radiomics signature may help with preoperative clinical decision-making for GEP-NETs.
Data on growing pancreatic cancer cases in young Americans shows that some cases are misattributed as early endocrine cancer.
Dr. Joseph Cullen discusses the combination of vitamin C with gemcitabine and nab-paclitaxel for pancreatic cancer.
The survival rate benefit increased over time for patients treated with TTFields, with a 13% improvement in OS at 12 months.
A recent study compared first-line chemotherapy, as the standard of care for PDAC, with other treatment options.
Entinostat has been utilized in other solid tumors for its ability to induce the inhibition of cell proliferation.
Study participants were administered nadunolimab with a standard dose of gemcitabine and nab-paclitaxel (GN) every two weeks.
Dr. Weinberg provides a recap of all of the GI oncology data of practice-changing potential presented at ESMO 2024.
Dr. Wungki Park gives an overview of the POLAR study for metastatic pancreatic cancer.
Dr. Wungki Park of Memorial Sloan Kettering Cancer Center discusses his trial on the use of ASP3082 for solid tumors.
The FAK inhibitor narmafotinib targets solid tumors in pancreatic cancer.
mFOLFIRINOX plus CRT did not improve R0 resection nor OS compared with nFOLFIRINOX without CRT.
The primary endpoint was PFS, which was a median of 3.5 months for S-1 and 3.7 months for 5-FU.
Dr. Wainberg reviews the data on GI malignancies and notes that it is unclear who should receive radiation before surgery.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.